ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ADVM Adverum Biotechnologies Inc

10.26
-0.17 (-1.63%)
Last Updated: 17:58:07
Delayed by 15 minutes
Share Name Share Symbol Market Type
Adverum Biotechnologies Inc NASDAQ:ADVM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.17 -1.63% 10.26 10.25 10.29 10.60 10.08 10.49 82,720 17:58:07

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Avalanche Biotechnologies, Inc. of Pendency of Class Action...

30/07/2015 7:05pm

PR Newswire (US)


Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Adverum Biotechnologies Charts.

NEW YORK, July 30, 2015 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:

Levi & Korsinsky, LLP

To: All persons or entities who purchased or otherwise acquired securities of Avalanche Biotechnologies, Inc. ("Avalanche") (NASDAQ: AAVL) pursuant and/or traceable to the Company's Initial Public Offering on or about July 31, 2014 and/or between July 31, 2014 and June 15, 2015.    

You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Northern District of California. If you purchased or otherwise acquired Avalanche securities pursuant and/or traceable to the Company's Initial Public Offering on or about July 31, 2014 and/or between July 31, 2014 and June 15, 2015, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/avalanche-technologies-aavl or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period defendants issued materially false and misleading statements and/or failed to disclose that Phase 2a of the study for its drug AVA-101 was not designed to show any statistical significance between the active and control groups in the secondary endpoints.  

If you suffered a loss in Avalanche you have until September 8, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:    
Levi & Korsinsky, LLP
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Logo - http://photos.prnewswire.com/prnh/20120409/MM84375LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-levi--korsinsky-llp-notifies-shareholders-of-avalanche-biotechnologies-inc-of-pendency-of-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-september-8-2015--aavl-300121440.html

SOURCE Levi & Korsinsky, LLP

Copyright 2015 PR Newswire

1 Year Adverum Biotechnologies Chart

1 Year Adverum Biotechnologies Chart

1 Month Adverum Biotechnologies Chart

1 Month Adverum Biotechnologies Chart

Your Recent History

Delayed Upgrade Clock